FENC Q2 2024 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+115.6% YoY

Gross Profit

$7M91.6% margin

Operating Income

-$5M-69.4% margin

Net Income

-$6M-76.5% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-71.4%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$925,000

Balance Sheet

Total Assets

$63M

Total Liabilities

$65M

Stockholders' Equity

-$1M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$3M	+115.6%
Gross Profit	$7M	$3M	+106.7%
Operating Income	-$5M	-$5M	-6.6%
Net Income	-$6M	-$6M	-0.7%